0.2785

21.62% 0.0495

After Hours: .28 0.0015 +0.54%

Cyclacel Pharmaceuticals Inc (CYCC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cyclacel Pharmaceuticals Inc stock is traded at $0.2785, with a volume of 3.71M. It is up +21.62% in the last 24 hours and down -7.17% over the past month. Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Previous Close:

$0.229

Open:

$0.234

24h Volume:

3.71M

Relative Volume:

11.55

Market Cap:

$43.77M

Revenue:

$74,000

Net Income/Loss:

$-13.43M

P/E Ratio:

-0.0296

EPS:

-9.4

Net Cash Flow:

$-10.54M

1W Performance:

+23.18%

1M Performance:

-7.17%

6M Performance:

-66.53%

1Y Performance:

-82.59%

1-Day Range:

$0.2263

$0.30

1-Week Range:

$0.2108

$0.30

52-Week Range:

$0.1706

$4.00

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name

Cyclacel Pharmaceuticals Inc

Sector

Healthcare (1176)

Industry

Biotechnology (677)

Phone

908-517-7330

Address

200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CYCC's Discussions on Twitter

Compare CYCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYCC Cyclacel Pharmaceuticals Inc	0.2785	43.77M	74,000	-13.43M	-10.54M	-9.40
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform
Apr-27-20	Resumed	ROTH Capital	Buy
Sep-07-18	Initiated	Ladenburg Thalmann	Buy
Oct-16-15	Initiated	H.C. Wainwright	Buy
Feb-04-10	Initiated	Roth Capital	Buy
Oct-28-09	Initiated	Merriman	Buy
Aug-12-08	Initiated	Piper Jaffray	Buy
Mar-12-08	Reiterated	Cantor Fitzgerald	Buy
Mar-12-08	Reiterated	Collins Stewart	Buy
Mar-12-08	Reiterated	Needham & Co	Buy
Nov-27-07	Reiterated	Cantor Fitzgerald	Buy
Aug-10-07	Reiterated	Cantor Fitzgerald	Buy
Jun-04-07	Reiterated	Needham & Co	Buy
Apr-23-07	Initiated	Lazard Capital	Buy
Apr-10-07	Initiated	Cantor Fitzgerald	Buy

View All

Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News

03:12 AM

Cyclacel Pharmaceuticals Inc Inc. (CYCC) Price Performance: A Technical Analysis Perspective - investchronicle.com

03:12 AM

01:22 AM

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Could Actually Go To 1 In 12 Months - Marketing Sentinel

01:22 AM

Apr 24, 2025

Was Cyclacel Pharmaceuticals Inc (CYCC)’s session last reading good? - uspostnews.com

Apr 24, 2025

StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Apr 24, 2025

Apr 23, 2025

Trading (CYCCP) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 23, 2025

Apr 21, 2025

Cyclacel Pharmaceuticals announces preferred stock dividend By Investing.com - Investing.com Canada

Apr 21, 2025

Apr 16, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World

Apr 16, 2025

Apr 07, 2025

When (CYCCP) Moves Investors should Listen - news.stocktradersdaily.com

Apr 07, 2025

Apr 05, 2025